Core Viewpoint - Health Road (02587) has announced a positive earnings forecast for the fiscal year 2025, expecting revenue of at least RMB 1.5 billion, a year-on-year increase of at least 25%, and a net profit of at least RMB 50 million, marking a significant shift from a "scale-driven" to a "profit-driven" business model [1] Group 1: Financial Performance - The company anticipates a net profit exceeding RMB 40 million in the second half of 2025, indicating a substantial improvement in profitability compared to the first half [1] - Content service revenue is projected to grow from RMB 577 million in 2024 to at least RMB 800 million in 2025, driven by a decentralized offline model [2] - Information technology service revenue is expected to rise from RMB 296 million in 2024 to at least RMB 350 million in 2025, benefiting from efficient AI operations [2] Group 2: Business Model and Strategy - The shift to a profit-driven model is characterized by the integration of content services, information technology services, AI software products, and operational efficiency improvements [1] - The company has established a robust network connecting over 12,000 hospitals and more than 900,000 registered doctors, facilitating resource integration and innovative service models [2] - The successful commercialization of AI products, generating approximately RMB 30 million in revenue in its first year, marks a significant milestone in technology monetization [2] Group 3: Operational Efficiency - The proportion of operating expenses to revenue decreased from 29% in 2024, enhancing net profit margins [3] - The company is expected to experience a significant reduction in marginal customer acquisition costs as it reaches a critical mass of connected hospitals [3] - The dual-agent model of "medical assistant + health manager" is anticipated to lower labor costs for health management institutions, indicating strong internal growth capabilities [3] Group 4: Market Position and Growth Potential - Health Road is positioned for high growth following its transition to profitability, with increasing certainty in net profit realization [4] - The company's unique position in the digital healthcare sector is expected to enhance its investment value as AI technology becomes more deeply integrated [4]

Core Viewpoint - Health Road (02587) has announced a positive earnings forecast for the fiscal year 2025, expecting revenue of at least RMB 1.5 billion, a year-on-year increase of at least 25%, and a net profit of at least RMB 50 million, marking a significant shift from a "scale-driven" to a "profit-driven" business model [1] Group 1: Financial Performance - The company anticipates a net profit exceeding RMB 40 million in the second half of 2025, indicating a substantial improvement in profitability compared to the first half [1] - Content service revenue is projected to grow from RMB 577 million in 2024 to at least RMB 800 million in 2025, driven by a decentralized offline model [2] - Information technology service revenue is expected to rise from RMB 296 million in 2024 to at least RMB 350 million in 2025, benefiting from efficient AI operations [2] Group 2: Business Model and Strategy - The shift to a profit-driven model is characterized by the integration of content services, information technology services, AI software products, and operational efficiency improvements [1] - The company has established a robust network connecting over 12,000 hospitals and more than 900,000 registered doctors, facilitating resource integration and innovative service models [2] - The successful commercialization of AI products, generating approximately RMB 30 million in its first year, marks a significant milestone in technology monetization [2] Group 3: Operational Efficiency - The proportion of operating expenses relative to revenue decreased from 29% in 2024, enhancing net profit margins [3] - The company is expected to experience a significant reduction in marginal customer acquisition costs as it reaches a critical mass of connected hospitals [3] - The dual-agent model of "medical assistant + health manager" is anticipated to lower labor costs for health management institutions, indicating strong internal growth capabilities [3] Group 4: Market Position and Growth Potential - Health Road is positioned for high growth following its transition to profitability, with increasing certainty in net profit realization [4] - The company's unique position in the digital healthcare sector is expected to enhance its investment value as AI technology becomes more deeply integrated [4]

Core Viewpoint - BrainCo (06681) has signed a strategic cooperation agreement with Kiang Wu Hospital in Macau to develop a comprehensive brain health service model focusing on cognitive impairment screening, assessment, training, and health management [1][4]. Group 1: Company Developments - BrainCo's stock price increased by 3.89%, reaching HKD 4.81, with a trading volume of HKD 71.89 million [1][4]. - The agreement with Kiang Wu Hospital aims to establish a long-term strategic partnership in Macau, creating a full-chain brain health service model that integrates hospitals, communities, and home care [1][4].

公开资料显示，健康160于2025年9月17日挂牌上市。浦银国际此前列出未来12个月限售股解禁市值较高 的部分港股公司，解禁比例高的个股在解禁前后股价或承压。其中，健康160将于9月17日解禁，解禁股 数2.67亿股，占流通股79%。 招股书显示，健康160是富有经验的中国医药健康用品批发商及领先的数字医疗综合服务提供商。公司 为客户提供各种医药健康用品，以及全面的数字医疗健康解决方案。截至2025年3月31日，健康160的平 台自成立以来已累计连接超过44,600家医疗健康机构，其中包括超过14,400家医院及超过30,200家基层 医疗卫生机构。 健康160(02656)重挫近40%，回吐年内多数涨幅，总市值一度跌穿200亿港元。截至发稿，跌32.1%，报 61.65港元，成交额3283.85万港元。 ...

Core Viewpoint - The company Brainstorm Aurora-B (06681) has signed a strategic cooperation agreement with the Macau Kiang Wu Hospital to establish a comprehensive brain health service model in the Macau region, focusing on digital screening, assessment, training, and health management for cognitive disorders [1] Group 1 - The company's stock rose by 4.32%, reaching HKD 4.83, with a trading volume of HKD 48.71 million [1] - The partnership with the influential private hospital in Macau is seen as a benchmark for the company, paving the way for future expansion in the Greater Bay Area [1] - This collaboration enhances the company's ecosystem alliance with authoritative medical institutions, complementing its recent national-level project cooperation with the National Rehabilitation Aids Research Center [1]

【新华社微特稿】韩国一家数字医疗初创企业9日说，已开发出一款基于人工智能(AI)的数字诊断平 台，可以帮助人们在家尽早发现心脏病发作的先兆。 这一诊断平台在1月的美国拉斯维加斯消费电子展（CES）上获得创新奖。该公司表示，希望通过推广 基于可穿戴设备的数字健康与医疗人工智能融合模式，加速构建以预防为核心的医疗生态系统，"在医 院之外守护生命安全"。（完）（乔颖） 韩联社报道，这家公司开发的平台可实时整合智能手表等可穿戴设备生成心电图数据，帮助使用者在家 庭环境中侦测21种心律失常类型，通过分析心电图数据来评估未来24小时内心脏骤停的可能性，并向患 者、主治医师及急救中心即时发出警报。 依照该公司说法，开发这一数字诊断平台旨在实现人们日常生活中的持续监测和预防性健康管理。 ...

依照该公司说法，开发这一数字诊断平台旨在实现人们日常生活中的持续监测和预防性健康管理。 这一诊断平台在1月的美国拉斯维加斯消费电子展（CES）上获得创新奖。该公司表示，希望通过推广 基于可穿戴设备的数字健康与医疗人工智能融合模式，加速构建以预防为核心的医疗生态系统，"在医 院之外守护生命安全"。 （文章来源：新华社） 韩国一家数字医疗初创企业9日说，已开发出一款基于人工智能(AI)的数字诊断平台，可以帮助人们在 家尽早发现心脏病发作的先兆。 韩联社报道，这家公司开发的平台可实时整合智能手表等可穿戴设备生成心电图数据，帮助使用者在家 庭环境中侦测21种心律失常类型，通过分析心电图数据来评估未来24小时内心脏骤停的可能性，并向患 者、主治医师及急救中心即时发出警报。 ...

脑动极光-B(06681)发布公告，公司的间接全资附属公司-脑动极光医学科技数智(澳门)有限公司(脑动极 光澳门)，已于近期与澳门镜湖医院正式签署《脑健康数字AI技术服务合作协议》。双方将围绕认知障 碍的数字筛查、评估、训练及全程健康管理，在澳门地区建立长期战略合作关系，共同构建覆盖"医院- 社区-家居"的全链条脑健康服务新模式。 根据该协议，本次合作将围绕以下核心内容展开：1.共建"健脑中心"与服务体系：双方将基于集团 的"六六脑科学健脑云服务"平台，在镜湖医院内设立并运营"健脑中心"。该中心将提供从早期筛查、精 准评估到数字化认知训练及病程随访的一站式服务，构建镜湖医院内部"早期筛查-精准诊断-多学科干 预-社区居家延伸"的全周期管理模式。 2.覆盖全年龄段的诊疗服务：服务对象包括60岁及以上的认知障碍风险人群及患者，以及3至18岁有神 经发育障碍的儿童患者。可根据医生处方，提供院内或居家形式的数字疗法治疗服务。 3.确保数据安全与合规：所有服务产生的数据将严格遵循澳门相关法律法规，在澳门本地进行服务器部 署与数据存储，实现数据完全本地化，不传输出境，保障信息安全与合规性。 4.联合科研与学术交流：双方将 ...

4. 联合科研与学术交流：双方将整合内地与澳门专家资源，共同推动脑健康医学中心建设，并开展相关 临床研究与合作，提升区域学术影响力。 董事会认为，此次合作对集团具有以下战略意义： 1. 树立标杆，开拓湾区市场：与澳门最具影响力的私立医院建立合作，成功打造了集团数字疗法在港澳 地区的首个标杆项目，为後续在粤港澳大湾区其他城市的拓展提供了可复制的示范模式。 格隆汇2月8日丨脑动极光-B(06681.HK)宣布，公司间接全资附属公司－脑动极光医学科技数智(澳门)有 限公司(「脑动极光澳门」)，已于近期与澳门镜湖医院(「镜湖医院」)正式签署《脑健康数字AI技术服 务合作协议》。双方将围绕认知障碍的数字筛查、评估、训练及全程健康管理，在澳门地区建立长期战 略合作关系，共同构建覆盖「医院 － 社区 － 家居」的全链条脑健康服务新模式。 根据该协议，此次合作将围绕以下核心内容展开： 1. 共建「健脑中心」与服务体系：双方将基于集团的「六六脑科学健脑云服务」平台，在镜湖医院内设 立并运营「健脑中心」。该中心将提供从早期筛查、精准评估到数字化认知训练及病程随访的一站式服 务，构建镜湖医院内部「早期筛查 － 精准诊断 － 多学科 ...

3.确保数据安全与合规：所有服务产生的数据将严格遵循澳门相关法律法规，在澳门本地进行服务器部 署与数据存储，实现数据完全本地化，不传输出境，保障信息安全与合规性。 智通财经APP讯，脑动极光-B(06681)发布公告，公司的间接全资附属公司-脑动极光医学科技数智(澳门) 有限公司(脑动极光澳门)，已于近期与澳门镜湖医院正式签署《脑健康数字AI技术服务合作协议》。双 方将围绕认知障碍的数字筛查、评估、训练及全程健康管理，在澳门地区建立长期战略合作关系，共同 构建覆盖"医院-社区-家居"的全链条脑健康服务新模式。 根据该协议，本次合作将围绕以下核心内容展开： 1. 共建"健脑中心"与服务体系：双方将基于集团 的"六六脑科学健脑云服务"平台，在镜湖医院内设立并运营"健脑中心"。该中心将提供从早期筛查、精 准评估到数字化认知训练及病程随访的一站式服务，构建镜湖医院内部"早期筛查-精准诊断-多学科干 预-社区居家延伸"的全周期管理模式。 2.覆盖全年龄段的诊疗服务：服务对象包括60岁及以上的认知障碍风险人群及患者，以及3至18岁有神 经发育障碍的儿童患者。可根据医生处方，提供院内或居家形式的数字疗法治疗服务。 2.积累 ...